key: cord-0788231-rwdzq935 authors: Bakchoul, Tamam; Hammer, Stefanie; Lang, Peter; Rosenberger, Peter title: Fibrinolysis shut down in COVID-19 patients: Report on two severe cases with potential diagnostic and clinical relevance date: 2020-08-26 journal: nan DOI: 10.1016/j.tru.2020.100008 sha: 775d3a3a592fcf0a694f2cef9cd589d95bb1237b doc_id: 788231 cord_uid: rwdzq935 nan 2 Dear Sirs, Accumulating evidence indicates an association between 2019-nCoV pneumonia and disseminated intravascular coagulation (DIC) [1, 2] . Although some controversy exists about the extent of DIC in COVID-19 [3] , DIC was indicated to be a strong predictor of mortality in patients developing pneumonia with this virus [1, 2, 4] . The pathophysiology of infection associated-DIC is complex and multifactorial, involving interplay between cellular and plasmatic elements of the hemostatic system and components of the innate immune response to the infecting pathogen [4, 5] . In this letter, we report on the viscoelastic properties of clots formed by COVID-19 patients. Using a novel method to assess clot formation a fibrinolysis shut down was observed. This finding has not been reported yet in COVID-19 infection and suggests that fibrinolysis system significantly contributes to the procoagulatory status in COVID-19 patients and might represent a therapeutic target. There is evolving evidence that a combination of activation events initiated by exposure of the endothelium, platelets, and leukocytes to pathogen-and damageassociated molecular patterns might be responsible for the uncontrolled activation of the coagulation system in severely ill COVID-19 patients [2, 4, 6] . To date most reports on COVID-associated coagulopathy focused an increased activation of the plasmatic coagulation system. Due to procoagulatory nature of COVID-19, anticoagulation in therapeutic concentration is common used in ICU-patients [6] [7] [8] . However, we observed low response to anticoagulants in COVID-19 patients, as represented by increasing D-Dimer values despite sufficient heparin plasma concentration. Our hypothesis was that a concurrent hyperfibrinolysis might explain these findings. Hyperfibrinolysis can be investigated using viscoelastic coagulation assays such as thromboelastography or rotation thromboelastometry. Both methods have been widely used in many fields of intensive care to guide hemostatic treatment in patients with bleeding [9] . However, little is known about their use to monitor patients with disposition to thromboembolic complications. In two COVID-19 ICU patients we observed a clot lysis shut down but not hyperfibrinolysis using a new viscoelastic test system. No relevant improvement of D-Dimer was observed despite UFH treatment (Table 1) . Extended laboratory investigation of cellular and plasmatic coagulation system was initiated and revealed acquired storage platelet disease and factor XIII deficiency. No hyperfibrinolysis was found when citrated blood was investigated using viscoelastic coagulation assay (maximal lysis [ML] in Ex-Text: 0%, Table 1 ). In contrast, we observed a remarkable resistance toward recombinant tissue plasminogen activator (tPA, lysis time [LT] in TPA-test: 910 sec, Table 1 ) and fibrinolysis shut down of the formed clot showed (ML in TPA-Text: 63%, Figure 1 ). These findings indicate an excessive procoagulation state despite an aPTT adjusted anticoagulation with UFH. On the next day, the patients developed bilateral arterial lung emboli and the anticoagulation was switched to argatroban due to suspected heparin induced thrombocytopenia (HIT). The laboratory investigations for HIT revealed negative results in the immunoassay and the functional assay (HIPA). The clinical situation did not improve despite therapy with catecholamine, continuous dialysis and the extension of anti-infective therapy, and patients died on day 32 of ICU stay. A 58-year-old man with no comorbidities was admitted to our ICU due to COVID-19 associated ARDS. Non-invasive ventilation did not improve the oxygenation status and venovenous extracorporeal membrane oxygenation (vv-ECMO) was implemented on day 4. Despite therapeutic anticoagulation with UFH, microthrombembolisms were found in liver and spleen using computer tomography leading to hepatic failure. Later on, the patient developed several episodes of transfusion-demanding bleedings (epistaxis, hematoma, catheter associated bleeding). Anticoagulation was switched to argatroban due to suspected J o u r n a l P r e -p r o o f 4 HIT. Extended laboratory investigations of cellular and plasmatic coagulation system were initiated and revealed factor XIII deficiency. The laboratory investigations for HIT revealed negative results in the immunoassay and HIPA. Interestingly, no hyperfibrinolysis was found using viscoelastic coagulation assay (ML in Ex-Text: 4%, Table 1 ). In contrast, the formed clot showed remarkable resistance toward tPA (LT: 610 sec in TPA-Test, ML: 94%, Figure 1 and Table 1 ). Anticoagulation with argatroban was continued and adjusted according to its plasma levels. On day 24 of the ICU stay, patient could be mobilized into seat and the vv-ECMO system was explanted. The impact of the plasminogen-plasmin-system on the procoagulatory status in trauma patients is relatively well established and was found to be associated with up to 17% mortality, mainly due to multiple organ failure [10, 11] . In our study, we used a tissue plasminogen activator challenge assay to unmask latent abnormalities in the plasminogenplasmin-system in COVID-19 patients. Interestingly, in both patients, laboratory findings were clinically supported by the development of relevant thromboembolisms. Of note, the cutoff for a fibrinolysis shutdown using thromboelastography has not been defined yet and depends largely on physician expertise. A recent report showed using rotational thromboelastometry a complete lack of spontaneous clot lysis (without addition of tPA) at 30 minutes in 57% of severe COVID-19 patients, which was associated with venous thromboembolic events [12] . Our work confirms this finding. However, since the pathophysiology of fibrinolysis shutdown in COVID-19 associated DIC has not been addressed yet, the molecular events need to be fully elucidated in further studies [13] . In general, upon thrombin generation fibrin polymerization occurs with considerable diversity, and the resulting viscoelastic properties are generally referred to as clot stability. Plasmin initially cleaves within the D regions of cross-linked fibrin resulting in a variety of fibrin degradation products such as D-dimer. There are a number of natural inhibitors that can attenuate plasmin activity such as α2-antiplasmin, thrombin-activatable fibrinolysis inhibitor, polyphosphate and plasminogen activator inhibitor (PAI-1). All these factors can enhance resistance to fibrinolysis [14] . To our knowledge, this is the first report on fibrinolysis shut down in COVID -19 patients. Our data suggest that abnormalities in fibrinolysis system contribute to the procoagulatory status in COVID-19 patients. Of note, recent studies showed that fibrinolytic therapy can improve survival in ARDS [15] and might be beneficial in COVID-19 patients [14, 16] . Although the optimal dosing regimen is still to be determined [14] , these data suggest that tPA might be a promising approach awaiting effective treatments for COVID-19. Viscoelastic coagulation assays could be used to monitor the efficacy of the fibrinolytic treatment and to predict thromboembolic complications in COIVID-19 patients. Taken together, our cases show that the dysregulated hemostasis in COVID-19-associated DIC is exacerbated by an inhibition of fibrinolysis and indicate the plasminogen-plasmin-system as a potential target to prevent thromboembolic complications in COVID-19 patients. Clinical features of patients infected with 2019 novel coronavirus in Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia Disseminated intravascular coagulation Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Followup COVID-19 and its implications for thrombosis and anticoagulation Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19 Sitz Tübingen Steuer-Nr We confirm that none of the authors of this manuscript has relevant COI related to this work. Yours sincerely, Tamam Bakchoul, MD, PhD Professor for Transfusion Medicine and Coagulation Disorders Medical Director of the Center for Clinical Transfusion Medicine University Hospital of Tübingen Medizinische Klinik Transfusionsmedizin Prof. Dr. med